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Supplementary Figure 1: Q-Q Plot 
Legend: Q-Q plot for association of 16 million SNPs with BCC, based on 
the Icelandic Discovery Two-Way Imputation data. Unadjusted P values 
are shown in black and P values adjusted using genomic control are shown 
in blue (λ=1.25). The expected (diagonal) values are indicated by a red 
line. The green line indicates the threshold for genome-wide significance 
based on Bonferroni correction for the 16 million SNPs tested (P = 3.0 x 
10
—9
). All SNPs exceeding this threshold mapped to the chromosome 17 
locus discussed in this report, or to previously published loci: 1p36 
(PADI6), strongest signal P = 3.5 x 10
—12
; 1q42 (RHOU), strongest signal 
P = 9.0 x 10
—11
; and 5p15 (TERT-CLPTM1L), strongest signal P = 9.0 x 
10
—12
 [Stacey et al., Nat Genet. 2008 Nov;40(11):1313-8; Rafnar et al., 
Nat Genet. 2009 Feb;41(2):221-7]. In order to roughly estimate the 
numbers of other loci detected at sub-genome wide significant signal 
levels, we divided the genome into 1Mb bins and determined how many 
such bins contained a SNP that exceeded a particular significance 
threshold. We observed that 475 bins contained SNPs with P < 10
—4
 and 
74 bins contained SNPs with P < 10
—5
.  
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Supplementary Figure 2: Venn diagram of Discovery Phase and Follow-up Phase Icelandic samples for BCC
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Supplementary Figure 2 Legend: A total of 4265 patients with BCC were ascertained from the Icelandic Cancer Registry. Of these 1366 were 
genotyped on Illumina SNP array platforms (―chipped‖). In the Discovery Phase (panel a) SNP genotypes were determined by imputation for the 1366 
cases who had been chip typed or by genealogy-based in silico genotyping for a further 755 cases (effective sample size, ESS, estimates are given for 
in silico genotyped sets). The combined sample that was genotyped by two-way imputation and used in the association analysis was 2121 cases (ESS). 
In the Follow-up Phase (panel b), all available cases (n = 2322) were genotyped for rs78378222 by Centaurus single-track assay. Of these, 1044 had 
not been typed on the Illumina SNP arrays and 1278 had. Genealogy-based in silico genotyping was used to obtain genotypes for a further 447 
individuals (ESS). Follow-up Phase two-way imputation and association analysis was carried out using all of the individuals who had been chip typed 
or who had been genotyped by genealogy-based in silico genotyping, yielding a total sample of 1813 cases (ESS). The Follow-up Phase single-track 
genotyping and association analysis was based on individuals who were directly genotyped by Centaurus assay and had not been chip typed (n=1044).  
Two different aspects of validation are examined in the Follow-up Phase: Biological validation (i.e. a further investigation of whether the allele 
frequencies differ between cases and controls) is examined by the 1044 single-track genotyped cases compared with single-track genotyped controls, as 
shown in Table 1. (Note that this is not a fully independent replication of the Discovery Phase result since some of the individuals who were assigned 
in silico genotypes in the Discovery Phase were subsequently single-track genotyped in the Follow-up Phase).  Technical validation refers to how well 
the imputed genotypes match the genotypes determined by direct single-track genotyping. This was assessed by examining rs78378222 genotypes for 
the 1278 cases (along with a further 8413 controls) who had been typed on both Illumina SNP array and Centaurus single-track platforms. The r
2
 
between the results of the two methods was 0.92. The process of defining Discovery Phase and Follow-up Phases for all other disease groups studied 
was carried out in an analogous manner to that described here for BCC. The numbers of cases in each group are detailed in Supplementary Table 4.  
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Supplementary Figure 3: The rs78378222 mutation impairs correct 3´ end processing of TP53 
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Supplementary Figure 3 Legend:  (a) Tukey box plot of quantitative RT-PCR of TP53 RNA abundance in peripheral blood samples. RNA levels 
were quantitated by RT-PCR and normalized against expression of GUSB. Normalized expression levels (y-axis) are plotted separately for each 
genotype (x-axis). The central horizontal line indicates the median of each distribution, upper and lower boundaries of the boxes indicate the 25
th
 and 
75
th
 percentiles and the whiskers indicate the 5
th
 and 95
th
 percentiles. N = 7 [C/A] heterozygotes and 51 [A/A] homozygotes. (b) Schematic diagram 
(not to scale) showing the locations of primers used for investigation of termination and polyadenylation of TP53 rs78378222 mutant and wild-type 
alleles. For the 3´ RACE, a gene specific primer was paired with the 3´ RACE primer in order to amplify specifically RNA species that were correctly 
polyandenylated. For the Run-on experiments, a gene specific primer was paired with the Run-on primer in order to amplify specifically RNA species 
that failed to terminate and polyadenylate correctly. (c) 3´ RACE of RNA samples from peripheral blood and adipose tissue from rs78378222 
heterozygotes produced 1300bp bands as expected for correctly terminated and polyadenylated mRNA. Sequencing of the 3´ RACE products showed a 
predominance of mRNAs bearing the wild type [A] allele and a reduced abundance of the mutant [C] allele for rs78378222 (arrowed). Data from 6 
replicate samples yielded an average ratio of 73% wild-type to 27% mutant transcripts (P = 1.6 x 10
—6
). Sequence traces of the reverse strand (and in 
genomic orientation, with the TP53 transcript running right to left) are shown for blood (upper) and adipose (lower) tissue-derived mRNA. (d) 
Sequence analysis of run-on transcription from an rs78378222 heterozygote. RT-PCR was conducted on blood and adipose-derived RNA using gene-
specific and Run-on primers. Sequence analysis of the products on both forward and reverse strands shows that the mutant [C] allele of rs78378222 
(arrowed) is predominant on run-on transcription products. Sequence traces are shown in genomic orientation with the TP53 transcript running right to 
left.  
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Supplementary Table 1: Association data for rs78378222[C] derived from all individuals who were genotyped by 
Centaurus single-track method
a
 
Tumour Type P-value OR 
95% 
Confidence 
Interval 
Number 
of Cases 
Frequency 
in Cases 
Number of 
Controls 
Frequency 
in Controls 
Basal Cell Carcinoma 4.74x10
-11
 2.11 (1.69,  2.64) 2322 0.0383 7200 0.0185 
Colorectal Adenoma 0.0031 1.42 (1.13,  1.79) 2396 0.0261 7200 0.0185 
Prostate Cancer 0.0096 1.36 (1.08,  1.72) 2445 0.0249 7200 0.0185 
Glioma 0.1460 1.81 (0.81,  4.03) 121 0.0331 7200 0.0185 
a
This set differs from the Iceland Follow-up Phase Single-Track Genotyped set in that it includes all cases who were 
single-track genotyped, without regard to whether or not they were also typed by Illumina chip. See Supplementary Figure 
2. 
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Supplementary Table 2: Overview of the replication sample sets used in this study  
Sample Set Disease/Phenotype Cases
a
 Controls
a
 Type Location Reference 
Denmark Basal Cell 
Carcinoma 
308 3,441 Nested Case Control Study from EPIC with 
supplementary population-based controls 
from Inter99 cohort 
Copenhagen, Denmark a,b 
Eastern Europe Basal Cell 
Carcinoma 
528 533 Multi-center Hospital-based Case: 
Population-based control 
Hungary, Romania, 
Slovakia 
c 
Spain Basal Cell 
Carcinoma 
628 3,928 Multi-center Hospital-based Case: 
Population-based control 
Zaragoza & Valencia, 
Spain 
d 
Netherlands  Prostate Cancer 1,085 1,796 Registry Ascertained Case: Population-
based Control 
Eastern Netherlands e 
Romania Prostate Cancer 639 815 Hospital-Based Case:Population Based 
Control 
Bucharest, Romania e 
Spain Prostate Cancer 785 1,787 Hospital-Based Case:Population Based 
Control 
Zaragoza, Spain e 
U.K. Prostate Cancer 521 1,407 PSA based testing and treatment trial Nine locations in the U.K. e 
U.S.A. Prostate Cancer 1,454 1,293 Hospital-Based Case:Control Chicago, U.S.A. e 
U.S.A. UCSF Glioma 658 573 Multi-center Hospital-based an Population-
based Case: Population-based control 
San Francisco Bay Area, 
U.S.A. 
f,g 
U.S.A. Mayo Clinic Glioma 530 283 Hospital-Based Case:Control Minnesota, U.S.A. f,g 
Netherlands Colorectal Cancer 464 1,796 Hospital-Based Case:Population Based 
Control 
Eastern Netherlands h 
Spain Colorectal Cancer 184 1,940 Hospital-Based Case:Population Based 
Control 
Zaragoza, Spain i 
Sweden Colorectal Cancer 1,781 1,737 Hospital-Based Case:Population Based 
Control 
Stockholm, Sweden j 
US Colon Cancer 475 807 Hospital-Based Case:Population Based 
Control 
North Carolina, U.S.A. k 
US Rectal Cancer 942 922 Hospital-Based Case:Population Based 
Control 
North Carolina, U.S.A. k 
Netherlands Breast Cancer 725 1,796 Registry Ascertained Case:Control Eastern Netherlands l 
Spain Breast Cancer 1,007 1,940 Hospital-Based Case:Population Based 
Control 
Zaragoza, Spain l 
Netherlands Melanoma 683 1,796 Registry Ascertained Case:Control Eastern Netherlands d 
Spain Valencia Melanoma 823 1,988 Hospital-Based Case:Population Based 
Control 
Valencia, Spain d 
Nature Genetics: doi:10.1038/ng.926
10 
 
Spain Zaragoza Melanoma 290 1,787 Hospital-Based Case:Population Based 
Control 
Zaragoza, Spain d 
Iceland 
Pigmentation 
Pigmentation Traits 9,805 NA Population-Based Self Reported 
Questionnaire 
Nationwide, Iceland m 
Netherlands Pigmentation Traits 1,326 NA Population-Based Self Reported 
Questionnaire 
Eastern Netherlands m 
a
Numbers successfully genotyped for rs78378222 are given    
References:       
(a) Vogel U. et al. Mutat Res 617, 138-46 (2007)     
(b) Glumer C. et al. Diabetes Care 26, 2335-40 
(2003) 
    
(c) Scherer, D et al. Int. J. Cancer 122, 1787-1793 (2008)    
(d) Stacey, S.N. et al., Nat Genet 41, 909-14 (2009)     
(e) Gudmundsson, J. et al. Sci Transl Med 2, 62ra92 
(2010) 
    
(f) Wrensch M. et al., Nat Genet 41, 905-8 (2009)     
(g) Jenkins R.B., et al., Cancer Genetics 204, 13-18 (2011)    
(h) van der Logt, E.M.J. et al. Carcinogenesis 25, 2407-15 (2004)    
(i) Rafnar, T et al. Nat Genet  41, 221-7 (2009)     
(j) Ghazi S. et al. Am J Pathol 177, 2688-93 (2010)     
(k) Satia J.A. et al. Cancer Epidemiol Biomarkers Prev 14, 429-36 (2005)   
(l) Stacey, S.N. et al. Nat Genet 39, 865-9 (2007)     
(m) Sulem, P. et al. Nat Genet 39, 1443-52 (2007)     
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Supplementary Table 3: Discovery Phase Two-Way Imputation association results for rs78378222[C] with BCC, 
colorectal adenoma, prostate cancer and brain cancers
a
 
Tumour Type P-value OR 
95% Confidence 
Interval 
Number 
of Cases 
Frequency 
in Cases 
Number of 
Controls 
Frequency 
in Controls 
Basal Cell Carcinoma 5.2x10
-17
 2.36 (1.93, 2.89) 2121
b
 0.0442 >39,614
b
 0.0192
c
 
Colorectal Adenoma 3.3x10
-4
 1.62 (1.24,  2.11) 3776
b
 0.0306 >37,417
b
 0.0192
c
 
Prostate Cancer 0.0016 1.39 (1.13,  1.71) 2708
b
 0.0265 >39,060
b
 0.0192
c
 
All Brain Cancers
d
 0.0018 2.18 (1.34,  3.56) 327
b
 0.0409 >20,824
b
 0.0192
c
 
a
Results are shown for tumour types that yielded significant associations after Bonferroni adjustment for the 20 types of 
tumour tested.
b
Effective sample size estimate taking into account efficiency of Icelandic genealogy-based in silico 
genotyping.
c
The control frequency given is derived from 40,309 directly chip-typed non-BCC control individuals.
d
ICD-10 
codes C70-C72 
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Supplementary Table 4: Numbers of samples analysed in Icelandic Discovery and Follow-up Phases 
  Phase: General Discovery Phase 
   B C D E F G H 
 
Phenotype 
Total Number 
of Cases 
Ascertained
a
 
Cases 
Chipped
b
 
Cases Not 
Chipped (B-C) 
Cases Not  
Chipped 
but with a 
FSDR
c 
on 
Chip 
Cases  
Genealogy-Based 
in silico 
Genotyped ESS
d
 
Cases Total 
ESS  (C+F) 
Matched 
Control ESS
e
 
 BCC 4265 1366 2899 1986 755 2121 >39,614 
 Prostate Cancer 5046 1860 3186 2231 848 2708 >39,060 
 Colorectal Adenoma 6703 2201 4502 3245 1233 3776 >37,417 
 All Brain Cancers 682 137 545 413 157 327 >20,824 
 Glioma 425 51 374 274 104 182 >10,353 
 Colorectal Cancer 3888 1128 2760 1836 698 1950 >40,547 
 Melanoma 1030 602 428 292 111 724 >41,073 
 Breast Cancer 5456 2414 3042 1952 742 3253 >39,261 
 ER Negative Breast Cancer 435 368 67 45 17 385 >41,216 
 High Risk Breast Cancer
f
 1739 875 864 563 220 1095 >40,250 
 
         Phase: Follow-up Phase 
  I J K L M N O P 
Phenotype 
Total Number 
of Cases 
Single Track 
Genotyped 
Cases 
Single 
Tracked but 
not Chipped  
Cases 
Single 
Tracked and 
Chipped 
Cases 
neither 
Chipped nor 
Single 
Tracked 
Cases neither 
Chipped nor 
Single Tracked 
but with a FSDR 
on Chip 
Cases  
Genealogy-
Based in silico 
Genotyped ESS 
 2-Way 
Imputation 
Cases Total 
ESS (C+N) 
2-Way 
Imputation 
Matched 
Control ESS 
BCC 2322 1044 1278 1855 1115 447 1813 >36,709 
Prostate Cancer 2445 635 1810 2550 1749 811 2671 >36,331 
Colorectal Adenoma 2396 1038 1358 2106 2237 856 3057 >36,022 
Glioma 121 72 49 302 207 84 135 >37,881 
a
Case ascertainment was through the Icelandic Cancer Registry or National Pathology Department registers. 
b
"Chipped" means that the samples were genotyped with Illumina Human 
Hap300, HapCNV370, Hap610, 1M or Omni-1 Quad bead chips. 
c"
FSDR" means first or second degree relative. 
d
"ESS" means effective sample size estimate. 
e
The matched control set 
(see Online Methods) was drawn from a total number of 437,218 population based controls, of whom 40,309 were chip typed and did not have a recorded BCC diagnosis. 
f
Probands
 
with breast cancer diagnosed under 50 years of age or a record of multiple independent primary breast cancers. 
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Supplementary Table 5 : Association between rs78378222[C] and colorectal cancer, breast cancer and melanoma 
   
Sample Set Tumour Type 
P-
value OR 
95% 
Confidence 
Interval 
Number 
of 
Cases 
Frequency 
in Cases 
Number 
of 
Controls 
Frequency 
in 
Controls Phet 
Iceland Discovery Phase Two-Way Imputation Colorectal Cancer 0.31 1.14 (0.89, 1.47) 1950
a
 0.0218 >40,547
a
 0.0192
b
 
 Netherlands Colorectal Cancer 0.87 0.95 (0.53,1.72) 464 0.0140 1796 0.0148 
 Spain Colorectal Cancer 0.052 3.54 (1.00,12.53) 184 0.0109 1940 0.0031 
 Sweden Colorectal Cancer 0.56 0.90 (0.63,1.27) 1781 0.0171 1737 0.0190 
 US Colon Cancer 0.20 1.95 (0.70,5.40) 475 0.0084 807 0.0043 
 US Rectal Cancer 0.50 0.81 (0.44,1.49) 942 0.0106 922 0.0130 
 Combined Icelandic Discovery and Replication Colorectal Cancer 0.51 1.06 (0.89, 1.27) 5796
a
 NA >47,749
a
 NA 0.23 
Iceland Discovery Phase Two-Way Imputation Breast Cancer 0.95 0.99 (0.80, 1.23) 3253
a
 0.0191 >39,261
a
 0.0192
b
 
 Netherlands Breast Cancer 0.33 1.27 (0.79, 2.03) 725 0.0186 1794 0.0148 
 Spain Breast Cancer 0.27 1.61 (0.69, 3.77) 1007 0.0050 1940 0.0031 
 Combined Icelandic Discovery and Replication Breast Cancer 0.57 1.06 (0.88, 1.27) 4985
a
 NA >42,995
a
 NA 0.40 
Iceland Discovery Phase Two-Way Imputation Melanoma 0.61 0.90 (0.60, 1.35) 724
a
 0.0173 >41,073
a
 0.0192
b
 
 Netherlands Melanoma 0.042 1.60 (1.02, 2.52) 683 0.0234 1796 0.0148 
 Spain Valencia Melanoma 0.25 0.60 (0.25, 1.43) 823 0.0036 1988 0.0060 
 Spain Zaragoza Melanoma 0.62 0.62 (0.09, 4.10) 290 0.0017 1787 0.0028 
 Combined Icelandic Discovery and Replication Melanoma 0.64 1.07 (0.81, 1.42) 2520
a
 NA >46,644
a
 NA 0.12 
a
Effective sample size taking into account efficiency of Icelandic genealogy-based in silico genotyping. 
b
The control frequency given is derived from 40,309 directly chip-
typed non-BCC control individuals. 
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Supplementary Table 6 : Specification of Nucleic Acid Sequences 
Description Sequence 
Sequence context of novel SNP chr17:7640788 cttcctgcccacgcccaccaagatgcattacctcttcaaccttcgagacatctccaaggtgactcgcggcctgaccttgccccttctgcttggcccagcctccg
cggaggctttctcttctcaaactaagccttaacactcactagcatg[C/T]gcaccaaaagtcacccccatgctgaagtgccacactccctggccttaccttta
aaacttctgggccaagtgcggtggctcacacctgtaattccagcactttgggaggccaacgcaggcagatcacctgaggttaggagttcaagaccag 
TP53 3´ RACE Gene-specific primer GAATGAGGCCTTGGAACTCAAGGAT 
TP53 Sequencing primer TTCCCCTCCTTCTCCCTTTTT 
Run-on primer TCCCGTAATCCTTGGTGAGA 
TP53 Internal primer for Run-on experiments TGCAAGCACATCTGCATTTT 
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Supplementary Note: Methods for Genotype Imputation 
Long range phasing: Long range phasing of all chip-genotyped individuals was performed 
with methods described previously
1,2
. In brief, phasing is achieved using an iterative 
algorithm which phases a single proband at a time given the available phasing information 
about everyone else that shares a long haplotype identically by state with the proband. Given 
the large fraction of the Icelandic population that has been chip-typed, accurate long range 
phasing is available genome-wide for all chip-typed Icelanders. For long range phased 
haplotype association analysis, we then partitioned the genome into non-overlapping fixed 
0.3cM bins. Within each bin, we observed the haplotype diversity described by the 
combination of all chip-typed markers in the bin. Haplotypes with frequencies over 0.001 
were tested in a case : control analysis. 
Genotype imputation: We imputed the SNPs identified and genotyped through sequencing 
into all Icelanders who had been phased with long range phasing using the same model as 
used by IMPUTE
1
. The genotype data from sequencing can be ambiguous due to low 
sequencing coverage. In order to phase the sequencing genotypes, an iterative algorithm was 
applied for each SNP with alleles 0 and 1. We let H be the long range phased haplotypes of 
the sequenced individuals and applied the following algorithm: 
1. For each haplotype h in H, use the Hidden Markov Model of IMPUTE to calculate for 
every other k in H, the likelihood, denoted γh,k, of h having the same ancestral source 
as k at the SNP. 
2. For every h in H, initialize the parameter θh, which specifies how likely the one allele 
of the SNP is to occur on the background of h from the genotype likelihoods obtained 
from sequencing. The genotype likelihood Lg is the probability of the observed 
sequencing data at the SNP for a given individual assuming g is the true genotype at 
the SNP. If L0, L1 and L2 are the likelihoods of the genotypes 0, 1 and 2 in the 
individual that carries h, then set . 
 
3. For every pair of haplotypes h and k in H that are carried by the same individual, use 
the other haplotypes in H to predict the genotype of the SNP on the backgrounds of h 
and k:  and . Combining these predictions 
with the genotype likelihoods from sequencing gives un-normalized updated phased 
genotype probabilities: , , 
 and . Now use these values to update θh and θk to 
 and . 
4. Repeat step 3 when the maximum difference between iterations is greater than a 
convergence threshold ε. We used ε=10−7. 
Given the long range phased haplotypes and θ, the allele of the SNP on a new haplotype h not 
in H, is imputed as . 
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The above algorithm can easily be extended to handle simple family structures such as 
parent-offspring pairs and triads by letting the P distribution run over all founder haplotypes 
in the family structure. The algorithm also extends trivially to the X-chromosome. If source 
genotype data are only ambiguous in phase, such as chip genotype data, then the algorithm is 
still applied, but all but one of the Ls will be 0. In some instances, the reference set was 
intentionally enriched for carriers of the minor allele of a rare SNP in order to improve 
imputation accuracy. In this case, expected allele counts will be biased toward the minor 
allele of the SNP. Call the enrichment of the minor allele E and let θ′ be the expected minor 
allele count calculated from the naïve imputation method, and let θ be the unbiased expected 
allele count, then and hence . 
This adjustment was applied to all imputations based on enriched imputations sets. We note 
that if θ′ is 0 or 1, then θ will also be 0 or 1, respectively.  
Using a sample of 9691 individuals who had been typed both on chip and by direct 
genotyping for rs78378222,  we compared the imputed genotype expectation values with 
direct single track genotypes. The r
2
 between the results of the two methods was 0.92.  
Genotype imputation information: The informativeness of genotype imputation was estimated 
by the ratio of the variance of imputed expected allele counts and the variance of the actual 
allele counts: 
 
where  is the allele count.  was estimated by the observed 
variance of the imputed expected counts and  was estimated by , where  is 
the allele frequency. 78.2 % of SNPs were imputed with information values  > 0.8 and a 
further 16.6% were imputed with information values > 0.6 and < 0.8. Thus 97.4% of SNPs 
were imputed with information values > 0.6. The information value for rs78378222 was 0.97. 
Genealogy-based in silico genotyping: In addition to imputing sequence variants from the 
whole genome sequencing effort into chip genotyped individuals, we also performed a 
second imputation step where genotypes were imputed into relatives of chip genotyped 
individuals, creating in silico genotypes. The inputs into the second imputation step are the 
fully phased (in particular every allele has been assigned its parent of origin
3
) imputed and 
chip type genotypes of the available chip typed individual. The algorithm used to perform the 
second imputation step consists of: 
1. For each ungenotyped individual (the proband), find all chip genotyped individuals 
within two meioses of the individual. The six possible types of two meiotic distance 
relatives of the proband are (ignoring more complicated relationships due to pedigree 
loops): Parents, full and half siblings, grandparents, children and grandchildren. If all 
pedigree paths from the proband to a genotyped relative go through other genotyped 
relatives, then that relative is excluded. E.g. if a parent of the proband is genotyped, 
then the proband’s grandparents through that parent are excluded. If the number of 
meiosis in the pedigree around the proband exceeds a threshold (we used 12), then 
Nature Genetics: doi:10.1038/ng.926
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relatives are removed from the pedigree until the number of meiosis falls below 12, in 
order to reduce computational complexity. 
2. At every point in the genome, calculate the probability of each genotyped relative 
sharing with the proband based on the autosomal SNPs used for phasing. A multipoint 
algorithm based on the hidden Markov model Lander-Green multipoint linkage 
algorithm using fast Fourier transforms is used to calculate these sharing 
probabilities
4,5
. First single point sharing probabilities are calculated by dividing the 
genome into 0.5cM bins and using the haplotypes over these bins as alleles. 
Haplotypes that are the same, except at most at a single SNP, are treated as identical. 
When the haplotypes in the pedigree are incompatible over a bin, then a uniform 
probability distribution was used for that bin. The most common causes for such 
incompatibilities are recombinations within the pedigree, phasing errors and 
genotyping errors. Note that since the input genotypes are fully phased, the single 
point information is substantially more informative than for unphased genotyped, in 
particular one haplotype of the parent of a genotyped child is always known. The 
single point distributions are then convolved using the multipoint algorithm to obtain 
multipoint sharing probabilities at the center of each bin. Genetic distances were 
obtained from the most recent version of the deCODE genetic map
6
. 
3. Based on the sharing probabilities at the center of each bin, all the SNPs from the 
whole genome sequencing are imputed into the proband. To impute the genotype of 
the paternal allele of a SNP located at , flanked by bins with centers at  and 
. Starting with the left bin, going through all possible sharing patterns , let  
be the set of haplotypes of genotyped individuals that share identically by descent 
within the pedigree with the proband’s paternal haplotype given the sharing pattern  
and  be the probability of  at the left bin – this is the output from step 2 above – 
and let  be the expected allele count of the SNP for haplotype . Then  is 
the expected allele count of the paternal haplotype of the proband given  and an 
overall estimate of the allele count given the sharing distribution at the left bin is 
obtained from . If  is empty then no relative shares with the 
proband’s paternal haplotype given  and thus there is no information about the allele 
count. We therefore store the probability that some genotyped relative shared the 
proband’s paternal haplotype,  and an expected allele count, 
conditional on the proband’s paternal haplotype being shared by at least one 
genotyped relative: . In the same way calculate  and . 
Linear interpolation is then used to get an estimates at the SNP from the two flanking 
bins:  
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If  is an estimate of the population frequency of the SNP then  is an estimate 
of the allele count for the proband’s paternal haplotype. Similarly, an expected allele count 
can be obtained for the proband’s maternal haplotype. 
Case : control association testing: Logistic regression was used to test for association 
between SNPs and disease, treating disease status as the response and expected genotype 
counts from imputation or allele counts from direct genotyping as covariates. Testing was 
performed using the likelihood ratio statistic. The conditional analysis of rs78378222 and  
chr17:7640788 was performed by adding rs78378222 as a covariate while testing 
chr17:7640788 for association with BCC. When testing for association using the in silico 
genotypes, controls were matched to cases based on the informativeness of the imputed 
genotypes, such that for each case  controls of matching informativeness where chosen. 
Failing to match cases and controls will lead to a highly inflated genomic control factor, and 
in some cases may lead to spurious false positive findings. The informativeness of each of the 
imputation of each one of an individual’s haplotypes was estimated by taking the average of 
 
over all SNPs imputed for the individual, where  is the expected allele count for the 
haplotype at the SNP and  is the population frequency of the SNP. Note that  
and . The mean informativeness values cluster into groups 
corresponding to the most common pedigree configurations used in the imputation, such as 
imputing from parent into child or from child into parent. Based on this clustering of 
imputation informativeness we divided the haplotypes of individuals into seven groups of 
varying informativeness, which created 27 groups of individuals of similar imputation 
informativeness; 7 groups of individuals with both haplotypes having similar 
informativeness, 21 groups of individuals with the two haplotypes having different 
informativeness, minus the one group of individuals with neither haplotype being imputed 
well. Within each group we calculate the ratio of the number of controls and the number of 
cases, and choose the largest integer  that was less than this ratio in all the groups. For 
example, if in one group there are 10.3 times as many controls as cases and if in all other 
groups this ratio was greater, then we would set  and within each group randomly 
select ten times as many controls as there are cases. For the different tumour types the value 
of was always higher than 15. 
Inflation Factor Adjustment: In order to account for the relatedness and stratification within 
the case and control sample sets we applied the method of genomic control based on chip 
typed markers
7
. The adjustment factors ranged from 1.06 (for PBC) to 1.27 (for Prostate 
Cancer). Quoted P values have been adjusted accordingly. 
Effective sample size estimation: In order to estimate the effective sample size of the case 
control association analyses, we compared the variances of the logistic and generalized linear 
regression parameter estimates based on the in silico genotypes to their one step imputation 
counterparts. For the quantitative trait association analysis, assume that a single step 
imputation (SNPs are imputed, but in silico genotypes are not used) association analysis with 
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 subjects leads on average to an estimate of the regression parameter with variance  and 
that the corresponding in silico genotype association analysis leads to an estimate of the 
regression parameter with variance , then assuming that variance goes down linearly with 
sample size we estimate the effective sample size in the in silico genotype association 
analysis as . For the case control association analysis, the number of controls is 
much greater than the number cases and we use the same formula to estimate the effective 
number of cases, with the -s representing the number of cases and the -s representing the 
variances of the logistic regression coefficient. 
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